External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>We recently initiated on Opthea. The Phase III biopharma is focused on developing OPT-302 for wet-AMD (age-related macular degeneration).</li><li> OPT-302 is a biologic inhibitor designed to trap VEGF-C/D and is used in combination with standard of care anti-VEGF-A therapies for wet AMD. </li><li>Overnight, Regeneron Pharmaceuticals (REGN-NASDAQ: US$716.90 | BUY, TP US$1152.00 | John Newman, Canaccord Genuity LLC, US), one of the market leaders in the anti-VEGF-A space released its 4Q result. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

We recently initiated on Opthea. The Phase III biopharma is focused on developing OPT-302 for wet-AMD (age-related macular degeneration). OPT-302 is a biologic inhibitor designed to trap VEGF-C/D and is used in combination with standard of care anti-VEGF-A therapies for wet AMD. Overnight, Regeneron Pharmaceuticals (REGN-NASDAQ: US$716.90 | BUY, TP US$1152.00 | John Newman, Canaccord Genuity LLC, US), one of the market leaders in the anti-VEGF-A space released its 4Q result. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Opthea Limited - Offshore Result: Implications from REGN 4Q24 Update

Opthea Ltd

Opthea Limited - Offshore Result: Implications from REGN 4Q24 Update